CD3 antigen inhibitors - Pipeline Insight, 2022

January 2022 | 60 pages | ID: C06FA70E9094EN
DelveInsight

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight’s, “CD3 Antigen Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in CD3 Antigen Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

CD3 Antigen Inhibitors Understanding

CD3 Antigen Inhibitors: Overview

Cluster of differentiation 3 (CD3) is a multimeric protein complex, known historically as the T3 complex, and is composed of four distinct polypeptide chains; epsilon (?), gamma (?), delta (?) and zeta (?), that assemble and function as three pairs of dimers (??, ??, ??). The CD3 complex serves as a T cell co-receptor that associates noncovalently with the T cell receptor

Function - In immunology, Cluster of differentiation 3 as T-cell co-receptor helps to activate the cytotoxic T-Cell. CD3 consists of a protein complex and is composed of four distinct chains. These chains associate with a molecule known as the T-cell receptor (TCR) and the ?-chain (zeta-chain) to generate an activation signal in T lymphocytes. The TCR, ?-chain, and CD3 molecules together constitute the TCR complex. The complex functions to transduce intracellular signals during TCR antigen recognition. CD3 epsilon is one of at least three invariant proteins that associate with the variable antigen recognition chains of the T cell receptor and function in signal transduction.

CD3 Antigen Inhibitors - The CD3 protein complex is an important T cell marker for the classification of malignant lymphomas and leukemias (T cell neoplasms). CD3 can also be used for the identification of T cells in coeliac disease, lymphocytic colitis and collagenous colitis. Animal studies have shown that anti-CD3 antibodies induce tolerance to allografts (Nicolls et al. 1993). OKT3, an anti-CD& antibody directed against CD3 ?, has been clinically approved for use in humans for the induction of immunosuppression in solid organ transplantation for the prevention and treatment of rejection. Interestingly, susceptibility to type I diabetes has been associated with the CD3 ? genetic locus and anti-CD3 antibodies have been shown to ameliorate the symptoms of this and other auto-immune disorders. New anticancer drug treatments are being developed based upon the CD3 (cluster of differentiation 3) T cell co-receptor, with molecules being designed for altering the co-stimulatory signal to help get the T-cell to recognize the cancer cell and become fully activated.

CD3 Antigen Inhibitors Emerging Drugs Chapters

This segment of the CD3 Antigen Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CD3 Antigen Inhibitors Emerging Drugs

• Tebentafusp: Immunocore

Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. The drug is currently in phase 3 stage of development.

• Cibisatamab: Roche

Cibisatamab is an intravenously administered T-cell bispecific monoclonal antibody, being developed by Roche for the treatment of Non-small cell lung cancer. Currently, it is in phase I/II stage of development.

Further product details are provided in the report……..

CD3 Antigen Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different CD3 Antigen Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on CD3 Antigen Inhibitors

There are approx. 20+ key companies which are developing the CD3 Antigen Inhibitors. The companies which have their CD3 Antigen Inhibitors drug candidates in the most advanced stage, i.e. phase IIIinclude, Immunocore.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

CD3 Antigen Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CD3 Antigen Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD3 Antigen Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD3 Antigen Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence CD3 Antigen Inhibitors R&D. The therapies under development are focused on novel approaches for CD3 Antigen Inhibitors.

CD3 Antigen Inhibitors Report Insights

• CD3 Antigen Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

CD3 Antigen Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing CD3 Antigen Inhibitors drugs?
• How many CD3 Antigen Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for CD3 Antigen Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CD3 Antigen Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CD3 Antigen Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Immunocore
• Roche
• Janssen Research & Development
• Celgene Corporation
• Avacta
• MacroGenics
• BioNTech
• Pfizer
• EpimAb Biotherapeutics
• Glenmark Pharmaceuticals
• Tiziana Life Sciences
• IGM Biosciences
• QLSF Biotherapeutics
• Y-mAbs Therapeutics
• Genmab
• YZY Biopharma
• Abzyme Therapeutics
• Harbour BioMed
• Aptevo Therapeutics
• IONTAS
• TeneoBio
• Cullinan Oncology

Key Products

• Tebentafusp
• Cibisatamab
• JNJ 78278343
• AVA 002
• MGD 014
• Glofitamab
• BNT142
• PF-06863135
• JNJ-64007957
• EMB-06
• EMB-07
• GBR 1302
• GBR 1342
• GBR 1372
• Foralumab
• IGM-2323
• QL315
• QL325
• Nivatrotamab
• huCD33-BsAb
• Epcoritamab
• M802
• HBM7020
• APVO436
• TNB-486
• Teclistamab
• CLN-049
• CLN-978

Contents

Introduction
Executive Summary
CD3 Antigen Inhibitors: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
CD3 Antigen Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  CD3 Antigen Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CD3 Antigen Inhibitors Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
Tebentafusp: Immunocore
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Teclistamab: Janssen Research & Development
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
  Comparative Analysis
Cibisatamab: Roche
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
BNT 142: BioNTech
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
CD3 Antigen Inhibitors Key Companies
CD3 Antigen Inhibitors Key Products
CD3 Antigen Inhibitors- Unmet Needs
CD3 Antigen Inhibitors- Market Drivers and Barriers
CD3 Antigen Inhibitors- Future Perspectives and Conclusion
CD3 Antigen Inhibitors Analyst Views
CD3 Antigen Inhibitors Key Companies
Appendix